Tumor Cell Marker PVRL4 (Nectin 4) Is an Epithelial Cell Receptor for Measles Virus by Noyce, Ryan S. et al.
Tumor Cell Marker PVRL4 (Nectin 4) Is an Epithelial Cell
Receptor for Measles Virus
Ryan S. Noyce
1,2, Daniel G. Bondre
1,2, Michael N. Ha
2,3, Liang-Tzung Lin
1,2, Gary Sisson
1,2, Ming-Sound
Tsao
3,4, Christopher D. Richardson
1,2,5*
1Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada, 2IWK Health Sciences Centre, Canadian Center for Vaccinology,
Halifax, Nova Scotia, Canada, 3Department of Medical Biophysics, University of Toronto, Toronto, Canada, 4Ontario Cancer Institute and Princess Margaret Hospital,
Toronto, Canada, 5Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada
Abstract
Vaccine and laboratory adapted strains of measles virus can use CD46 as a receptor to infect many human cell lines.
However, wild type isolates of measles virus cannot use CD46, and they infect activated lymphocytes, dendritic cells, and
macrophages via the receptor CD150/SLAM. Wild type virus can also infect epithelial cells of the respiratory tract through an
unidentified receptor. We demonstrate that wild type measles virus infects primary airway epithelial cells grown in fetal calf
serum and many adenocarcinoma cell lines of the lung, breast, and colon. Transfection of non-infectable adenocarcinoma
cell lines with an expression vector encoding CD150/SLAM rendered them susceptible to measles virus, indicating that they
were virus replication competent, but lacked a receptor for virus attachment and entry. Microarray analysis of susceptible
versus non-susceptible cell lines was performed, and comparison of membrane protein gene transcripts produced a list of
11 candidate receptors. Of these, only the human tumor cell marker PVRL4 (Nectin 4) rendered cells amenable to measles
virus infections. Flow cytometry confirmed that PVRL4 is highly expressed on the surfaces of susceptible lung, breast, and
colon adenocarcinoma cell lines. Measles virus preferentially infected adenocarcinoma cell lines from the apical surface,
although basolateral infection was observed with reduced kinetics. Confocal immune fluorescence microscopy and surface
biotinylation experiments revealed that PVRL4 was expressed on both the apical and basolateral surfaces of these cell lines.
Antibodies and siRNA directed against PVRL4 were able to block measles virus infections in MCF7 and NCI-H358 cancer cells.
A virus binding assay indicated that PVRL4 was a bona fide receptor that supported virus attachment to the host cell. Several
strains of measles virus were also shown to use PVRL4 as a receptor. Measles virus infection reduced PVRL4 surface
expression in MCF7 cells, a property that is characteristic of receptor-associated viral infections.
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Introduction
In spite of the success of an attenuated measles virus (MV)
vaccine in the modern world [1] measles virus (MV) is still a major
killer of children in developing countries [2]. MV strikes an
estimated 20 million children a year and killed around 164,000
individuals in 2008 according to the World Health Organization
(http://www.who.int/mediacentre/factsheets/fs286/en/). MV
causes an acute disease characterized by fever, photophobia,
coughing, running nose, nausea, and a macular red rash over most
of the body. In rare instances, persistent MV infections can occur
in the brain and lead to encephalitis. Humans and monkeys are
hosts for MV [3-7] while most rodents are not normally infected
by the virus [8–10]. The recent discovery that attenuated strains of
MV possess oncolytic properties and can be used to destroy tumor
cells, has kindled an interest in this virus as a gene therapy agent
[11,12].
Measles virions contain a negative strand RNA genome from
which viral mRNAs are transcribed to encode a nucleocapsid
protein (NP), a phosphoprotein (P), virulence factors (C and V),
matrix protein (M), membrane fusion protein (F), the hemagglu-
tinin/receptor binding protein (H), and an RNA polymerase (L)
[13]. Surrounding the nucleocapsid is a membrane which contains
the two viral glycoproteins, H and F. The H protein is required for
viral attachment to the host cell receptor, while F mediates
membrane fusion and entry at the host plasma membrane and is
also responsible for syncytia (multi-nucleated cell) formation.
Interaction of the H protein of MV with a cellular attachment
factor is the initial event of infection. The binding of H to the host
cell receptor triggers and activates the F protein to induce fusion
between virus and host cell membranes [14–16]. The search for
MV cellular receptors initially began with vaccine/laboratory
strains and progressed to more relevant receptors used by wild
type MV (wtMV) isolates [17]. Human membrane cofactor
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tory/vaccine strain of MV [18,19]. CD46 is a complement
regulatory protein that is expressed on most cell types in the
human body, with the exception of red blood cells (although it is
on monkey erythrocytes) [20]. Natural isolates of wtMV can be
adapted to grow in Vero monkey kidney cells and this is
accompanied by mutations in the H protein that convey the
CD46 receptor binding phenotype [21–23]. Strains of wtMV are
routinely isolated in marmoset B95-8 cells, a B cell line
immortalized with Epstein-Barr virus, which allows the virus to
grow without the need for adaptation [24]. These isolates cannot
use CD46 as a receptor [22,25]. Our laboratory and others
hypothesized that another lymphotropic receptor could be used
by wild type isolates of MV [22,26,27]. Signaling lymphocyte
activation molecule (SLAM) or CD150 was identified to be a
lymphotropic receptor for both clinical isolates and vaccine
strains of MV [28–30]. SLAM/CD150 is a signaling molecule
that is expressed on activated B, T, monocyte, and dendritic cells
[31].
Recent evidence indicates that CD150
+ alveolar macrophages,
dendritic cells, and lymphocytes are the initial targets for measles
virus infections in macaques [32–35]. However, wild type MV, in
autopsied human patients and some experimentally infected
monkeys, has been shown to infect the epithelial cells of the
trachea, bronchial tubes, lungs, oral cavity, pharynx, esophagus,
intestines, liver, and bladder [36,37]. These epithelial cells do not
express SLAM/CD150, but the infected cells do shed virus [37–
39]. Epithelial cells may be important later on in infection and for
the spread of MV by aerosol droplets. Wild type MV does not
readily infect most common laboratory epithelial, endothelial, or
fibroblast cell lines. In addition, cryo-preserved primary human
small airway epithelial cells (SAEC) grown in serum free epithelial
cell growth medium are not normally susceptible to wtMV, but
can be made susceptible by culturing them in 2% fetal calf serum
[39]. These cells do not express CD150/SLAM and the wtMV
cannot use CD46/MCP, suggesting that there is another receptor
on epithelial cells [39]. The third receptor has been postulated to
lie on the basolateral side of epithelial cells in close context to
infected lymphocytes and dendritic cells, and it may play a
secondary role following infection of the lymphatic system that is
important for MV transmission [33,34,40–42]. Virus is postulated
to infect epithelial cells using the unidentified basolateral receptor,
and MV is subsequently shed from the apical surface of these cells
[33,42,43]. Other investigators have been searching for an elusive
receptor on polarized epithelial and cancer cell lines [41,44–46].
Recently it was shown that loss of tight junction proteins, during
an epithelial-mesenchymal cell transition induced by the tran-
scription repressor SNAIL, blocked infections by wtMV [45]. It
has become clear that tight junction proteins can serve as entry
factors for other viruses that target polarized epithelial cells. These
include hepatitis C virus, reovirus, herpes simplex virus and
coxsackie virus [47–50]. The region of the H protein that interacts
with the putative epithelial receptor was recently mapped on the 3-
D structure of the viral attachment protein to include residues
I456, L464, L482, P497, Y541, and Y543 [33,41].
Here we show that wild type MV infects primary airway
epithelial cells grown in fetal calf serum and many adenocarci-
noma cell lines of the lung, breast, and colon. A microarray
analysis of susceptible versus non-susceptible cell lines showed
that transcripts for many adherens junction and tight junction
proteins are up-regulated in virus receptive cells. However, the
integrity of these junctions was not a prerequisite for infection.
Non-susceptible cell lines could be infected following transfection
with a CD150/SLAM expression vector, indicating that they
were replication competent. Analysis of the microarray data,
filtered for membrane protein genes, produced a short list of 11
candidate receptors. Of these only human PVRL4 (Nectin 4), a
tumor cell marker found on breast, lung, and ovarian
carcinomas, rendered cells amenable to MV infections. Transient
knockdown of PVRL4 using siRNA abolished wtMV infection in
these cell lines. The identification of this receptor could provide
impetus for MV as an oncolytic treatment for lung, breast, and
colon adenocarcinomas.
Results
Wild type MV infects serum activated SAEC
independently of CD46 (MCP) and CD150 (SLAM)
Human primary SAEC were previously shown to support
wtMV replication and produce syncytia when grown in the
presence of 2% fetal calf serum but not in serum free media. These
cells did not express CD150 (SLAM) [39]. We confirmed these
results and further demonstrated that infections with a recombi-
nant wtMV engineered to express EGFP (IC323-EGFP wtMV)
were independent of CD46 (MCP) and CD150 (SLAM)
expression. Infections with IC323-EGFP wtMV were unaffected
by the presence of monoclonal antibodies directed against CD46
and CD150, that were previously shown to neutralize MV
infections [44,51] (Figure 1A). SLAM blind virus, which contains
mutations in the H protein that prevents CD150 recognition,
along with an EGFP reporter gene [52], also infected these cells.
Marmoset cell lines do not express the critical SCR1 virus binding
domain of CD46 [53,54]. Deletion of SCR1 in the marmoset
SAEC was confirmed by diagnostic RT-PCR of CD46 mRNA
using conserved primer sequences (Figure 1B). However, marmo-
set SAEC were still susceptible to IC323-EGFP wtMV (Figure 1B).
The marmoset cells could also be infected with Edmonston-EGFP,
SLAM blind and CD46 blind recombinant MV [52] (Figure 1B).
These results provide further support for the existence of a unique
MV epithelial cell receptor.
Author Summary
Measles virus is a primate-specific virus that causes acute
respiratory disease and can also lead to short term
immune suppression resulting in secondary infections by
bacteria or parasites. Wild type measles virus attaches to
and infects lymphocytes using the receptor CD150
(signaling lymphocyte activation molecule, SLAM). Measles
virus is also known to infect epithelial cells of the upper
respiratory system and lungs. However, the viral receptor
on these cells was previously unknown. Adenocarcinomas
are derived from glandular epithelial cells of organs
including the lung, breast, or colon. We showed that wild
type isolates of measles virus can infect human airway
epithelial cells and many adenocarcinoma cell lines. A
comparative analysis of membrane genes expressed in
cells susceptible and non-susceptible for measles virus
infections revealed candidate receptor proteins. Only
PVRL4 (Nectin 4) converted cells that were resistant to
measles viral infections, to cells that could support virus
infections. PVRL4 is a tumor cell marker that is highly
expressed on embryonic cells such as those of the
placenta, but it is also expressed at lower levels in the
trachea, oral mucosa, nasopharynx, and lungs. It is highly
expressed on many lung, breast, colon, and ovarian tumors
suggesting that they could be targeted with oncolytic
measles virus.
PVRL4 (Nectin 4) Is A Receptor for Measles Virus
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Tissue Type Cell Line Tumour Type % Infection
Efficiency
Lung MGH24 adenocarcinoma +++++
NCI-H358 adenocarcinoma +++++
NCI-H125 adenocarcinoma ++++
Calu-3 adenocarcinoma ++++
RVH6847 adenocarcinoma +
A549 adenocarcinoma -
SBC-3 small cell carcinoma -
MGH7 squamous cell carcinoma -
NCI-H157 squamous cell carcinoma -
NCI-H460 large cell carcinoma -
NCI-H661 large cell carcinoma -
NCI-H520 squamous cell carcinoma -
NCI-H226 squamous cell carcinoma -
Breast MCF7 adenocarcinoma +++++
MDA-MB-468 adenocarcinoma +++++
T47D adenocarcinoma ++++
MDA-MB-231 adenocarcinoma -
Colon DLD-1 adenocarcinoma +++++
LoVo adenocarcinoma +++++
T84 adenocarcinoma ++++
HT29 adenocarcinoma ++++
HCT116 adenocarcinoma -
Liver Huh7 adenocarcinoma +
Hep3B adenocarcinoma +
Pancreas HS766T adenocarcinoma -
Cervix HeLa adenocarcinoma -
Kidney MDCK (dog) n.a. +/2
Vero (green monkey) n.a. +/2
HEK 293 (human) n.a. +/2
COS-1 (green monkey) n.a. +/2
OMK (owl monkey) n.a. -
NZP60 (marmoset) n.a. -
BHK21 (hamster) n.a. +/2
Ovary CHO (hamster) n.a. -
See also Figure S1 in Text S1.
+++++ 100% cells infected; ++++ 80% cells infected; +++ 60% cells infected; ++ 40% cell infected; + 20% cells infected; +/2 5% cells infected; - 0% cells infected.
doi:10.1371/journal.ppat.1002240.t001
Figure 1. A new receptor for MV is present on smooth airway epithelial cells (SAEC). (A) Human SAEC were incubated with receptor
neutralizing antibodies against CD46 (M75 and B97) or CD150 (IPO-3 and A12) and challenged with the Edmonston vaccine, CD150 Blind, or IC323
wild type strains of MV. Each virus strain contained the EGFP reporter gene. In virus control experiments antibodies against CD46 inhibited infection
by Edmonston MV in HeLa cells while antibodies against CD150 blocked infection of Vero-CD150/SLAM by wild type IC323 MV. (B) Marmoset SAEC
contain a deletion of the SCR1 domain of CD46 and do not express CD150/SLAM. The panel on the right shows a diagnostic PCR spanning the SCR1
domain revealed by agarose gel electorphoresis in the presence of ethidium bromide, that confirms the deletion in marmoset SAEC. However, the
marmoset SAEC could be infected with either the Edmonston or IC323 strains of MV. Virus containing H protein that was mutated in either its CD150
binding site (CD150 Blind) or its CD46 binding site (CD46 Blind) also replicated in the marmoset SAEC. Scale bar=100 mm.
doi:10.1371/journal.ppat.1002240.g001
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lung, breast, and colon tumors
Since adenocarcinomas are defined as tumors which are derived
from glandular epithelial cells, we decided to test the susceptibility
of a number of different tumor cell lines to infection with IC323-
EGFP wtMV. Infectivity assays were performed on 12 lung, 4
breast, 6 colon, 3 liver, 1 pancreatic, 1 cervix and 5 kidney cell
lines. The relative infectivity in the different cell lines was assessed
qualitatively, as the percentage of fluorescent cells due to virus-
mediated EGFP expression (Table 1). Most adenocarcinomas were
susceptible to IC323-EGFP MV infection, and the exceptions were
A549 (lung), MDA-MB-231 (breast), HCT116 (colon), HepG2
(liver), HS766T (pancreas), and HeLa (cervix) cells, which were
non-susceptible to the virus (Figure S1 in Text S1). Large cell and
small cell carcinoma cell lines from the lung also did not support
infection. To determine whether the non-susceptible property of
negative cell lines was due to the absence of a particular receptor,
non-susceptible cell lines were transfected with a cDNA expression
plasmid for the lymphotropic receptor CD150/SLAM. Expression
of CD150 rendered A549, MDA-MB-231, HeLa, Vero, and
OMK cells susceptible to IC323-EGFP wtMV, indicating that the
cells were competent for MV replication, but lacked the entry
protein(s) for viral infection (Figure S2 in Text S1).
Microarray analysis reveals that PVRL4 (Nectin 4) is a
receptor for wtMV
Microarray analysis and a comparison between susceptible and
non-susceptible cells were previously used to identify the cellular
receptor for Nipah virus [55]. In our case the mRNA transcripts
from cells that were susceptible to wtMV infection were compared
to those from non-susceptible cells using the Affymetrix Human
Gene ST 1.0 Array. RNA was prepared from breast adenocar-
cinoma (MCF7, MDA-MB-468, T47D, MDA-MB-231), lung
adenocarinoma (NCI-H358, MGH24, NCI-H125, A549), and
SAEC (with and without serum treatment) cell lines. Following the
analysis it was apparent that many of the up-regulated membrane
proteins were associated with the tight junctions and adherens
junctions found in polarized epithelial cells (Table S1). Recently
another laboratory reported that loss of tight junctions, during an
epithelial-mesenchymal cell transition induced by the transcription
repressor SNAIL, blocked receptor-dependent infections by wtMV
[45]. The percentage up-regulation of gene expression for
membrane proteins in susceptible cells compared to non-
susceptible cells was calculated for breast, lung, and SAEC
categories of cell lines (Table S1). These values were ordered and
only gene products which were up-regulated greater than 20%
were considered in our analysis. Evaluation of potential receptors
was conducted in 2 phases. Gene products that were up-regulated
in susceptible breast adenocarcinomas were first compared to
those up-regulated in susceptible lung adenocarcinomas. To
investigate whether this subset of candidate receptor genes from
the initial microarray screens might act as an epithelial receptor
for wtMV, we cloned these genes from a cDNA library of
membrane proteins from Open Biosystems (Huntsville, AL) or
purchased the genes not represented in this library from Origene
Systems (Rockville, MD). We chose to introduce the expression
plasmids into COS-1 monkey kidney cells due to their high
transfection efficiency. Expression of the individual candidate
receptor genes was verified by Western immunoblot analysis for
the V5 peptide tag that was fused to the carboxy terminus of each
membrane protein from the Open Biosystems vectors or the Myc-
DDK(Flag) tag from the Origene vectors (Figure 2, Figure S3 in
Text S1). At 36 hours post-transfection, COS-1 cells were
inoculated with wtMV-EGFP and infections were monitored
between 24-72 hours p.i. Over 48 membrane protein genes that
were the most highly up-regulated in both breast and lung
adenocarinoma cells were originally tested without success
(indicated with * in Table 2). Subsequently, in the next phase of
testing, the up-regulated genes common to both breast and lung
adenocarcinomas were compared to those in serum activated
SAEC cells. The results are presented in Table 2, and 11 common
gene products were over-expressed in all 3 tissue types. These
candidate receptor genes included SLC6A14, STEAP4,
TMPRSS11E, MUC1, ERBB3, PVRL4, MUC15, PCDH1,
ANO1, MUC20, and CLDN7. Of these, 10 were tested (indicated
with ** in Table 2) and it became immediately evident that
PVRL4 could act as a receptor and facilitate infection (Figure 2).
(Both PVRL4 (Nectin 4) and the CD150/SLAM positive control
yielded infections that were characterized by syncytia formation
with typical MV cytopathology. A background of single infected
COS-1 cells which did not fuse and form syncytia was also evident.
Infections in these cells did not progress and could be due to
another route of entry such as macropinocytosis. These single
infected cells were previously reported in MV infected CHO and
Vero monkey kidney cells and occurred at frequency of 2–3 logs
below that of SLAM-dependent infections [44]. This background
could not be eliminated with siRNAs directed against PVRL4
(data not shown). Expression of exogenous PVRL4 in other non-
susceptible cell lines (OMK, HeLa, A549, and MDA-MB-231) also
rendered them susceptible to IC323-EGFP wtMV infection
(Figure S2 in Text S1).
Related proteins (PVR, PVRL1, PVRL2, PVRL2) cannot
function as a receptor for wtMV
PVR, PVRL1, PVRL2, and PVRL3 are nectin proteins that are
closely related in structure and sequence to PVRL4 (Figure S4 in
Text S1). The proteins PVR, PVRL1, and PVRL2 have
previously been shown to function as receptors for polio (PVR)
and herpes simplex (PVRL1, PVRL2) viruses. We tested the
ability of PVR, PVRL1, PVRL2, and PVRL3 to function as
receptors for MV following transfection into COS-1 cells.
Fluorescence microscopy of non-permeabilized cells that over-
expressed PVRL1, PVRL2, PVRL3, and PVRL4 confirmed cell
surface expression of these proteins (data not shown). Only
PVRL4 was capable of converting the non-susceptible cells to a
wtMV susceptible phenotype (Figure 3A). Infected cells expressing
PVRL4 produced virus particles based upon plaque assays
(Figure 3B). Expression of the various nectin proteins was
Figure 2. PVRL4 (Nectin 4) can function as an entry factor for IC323-EGFP wtMV. COS-1 cells were transfected with expression plasmids
containing the coding sequences for candidate membrane protein receptors. After 36 hrs the cells were infected with IC323-EGFP wtMV. Virus
specific fluorescence was observed between 24–48 hrs infection at 100x magnification using a Leica inverted microscope. Both PVRL4 (Nectin 4) and
the positive control CD150/SLAM were capable of converting the non-susceptible COS-1 cells to a virus susceptible phenotype that produced
syncytia. Other candidate receptor proteins including SLC6A14, STEAP4, TMPRSS11E, MUC1, ERBB3, and MUC20 were ineffective in producing
infections, and yielded only isolated background single-cell infections that did not produce syncytia. Whole cell protein lysates were separated by
SDS-PAGE followed by Western Immunoblot using Flag (IB: DDK) and V5 (IB: V5) antibodies to detect expression of these candidate receptors. GAPDH
was used as a loading control. Scale bar=100 mm. See also Figures S2 and S3 in Text S1.
doi:10.1371/journal.ppat.1002240.g002
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Common Genes
Up-regulated in
Breast & Lung Cells
% Gene
Up- Regulation
in Breast Cells
% Gene
Up- Regulation
in Lung Cells
Common Genes
Up-regulated in
Breast, Lung, SAEC
% Gene
Up- Regulation
in SAEC
SLC6A14* 173.1415 61.90872 SLC6A14** 46.87437
RAB25 * 161.964 188.6348
CDH1* 131.1153 45.16778
GPC4* 103.9329 129.3733
STEAP4* 100.7787 109.9432 STEAP4** 64.64598
TMPRSS11E* 96.91898 118.1558 TMPRSS11E** 46.68319
NCAM2* 94.40557 43.07266
CDH3* 93.77679 123.3686
FXYD3 86.12615 41.92274
MUC1* 75.34311 49.158 MUC1** 32.83022
MME 73.32612 82.94319
ERBB3* 72.10978 45.78744 ERBB3** 23.24152
PCDHB8* 70.45194 89.7596
ST14* 68.33217 106.8741
GABRA3 65.42129 50.05689
PRSS8 58.427 52.65615
PCDHB4* 57.51795 53.33358
SLC16A14* 55.81763 38.13178
ANK3 51.61145 44.22223
PVRL4 50.68993 38.80007 PVRL4** 27.6538
MUC15* 47.35872 60.32913 MUC15** 23.22254
SYK 47.19083 68.0141
SCNN1A* 47.04117 64.89888
PCDH1* 41.70316 41.02153 PCDH1** 22.85412
FAP 40.45849 38.08091
OR8G5 40.37826 51.7274
ANO1 38.69293 45.62884 ANO1 40.30204
MUC20* 37.97506 45.12805 MUC20** 44.45975
PROM2* 37.844 50.14194
SUSD4* 37.46031 27.36689
EPCAM* 37.39759 116.3044
FGFBP1* 36.91295 38.48566
EPHA1* 35.75165 50.02149
EPCAM * 35.06523 95.96663
ENPEP 34.85825 77.82285
IGSF9 34.23295 35.2908
CHRM3 32.84461 47.77368
PCDHB15 30.85493 45.72636
CLDN7* 29.9608 84.29241 CLDN7** 26.90155
RAB19 28.47934 39.00469
DSC2 27.83151 45.32287
MMP16 27.7552 27.27076
PSD4 26.42839 37.93089
MAL2* 25.88348 184.0902
GJB5 25.58353 43.39558
GPR81 25.39142 115.9613
ADAP1 25.17025 43.49649
VEPH1 24.12028 35.18223
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antibodies directed against the DDK tag (Figure 3C). Cells
containing PVRL4 but not the other nectins also synthesized MV
proteins as shown by an immunoblot for viral matrix (M) protein
(Figure 3D).
Susceptible but not non-susceptible cell lines express
PVRL4 (Nectin 4) on their cell surface
Flow cytometry was used to determine whether epithelial or
adenocarcinoma cells that are susceptible for wtMV infection
expressed PVRL4 on their surfaces. Cells susceptible for wtMV
infection bound fluorescent antibodies specific for PVRL4
(Figure 4A). Non-susceptible cells, on the other hand, exhibited
no difference in fluorescence when compared to the isotype
control antibody (Figure 4B). NCI-H358, NCI-H125, MGH24,
and Calu-3 lung adenocarcinoma cells expressed PVRL4 while
A549 adenocarcinoma, squamous cell (NCI-H157), small cell
(SBC-3), and large cell (NCI-H460) lung carcinomas did not.
MCF7, MDA-MB-468, and T47D breast adenocarcinomas were
PVRL4 positive, while the non-susceptible MDA-MB-231 cells
were not. Of the colon tumor cell lines, HT29, T84, and DLD-1
cells were positive for PVRL4, while HCT116 cells were negative.
Other adenocarcinomas of the liver (HepG2), cervix (HeLa), and
kidney epithelial cell lines were negative for PVRL4 on their
surfaces. Interestingly, SAEC treated with FCS for 24 h exhibited
an increased level of PVRL4 on their surface (SAEC + FCS),
whereas the SAEC cultured in the absence of serum did not. Since
we and others have shown that SAEC grown in the presence of
serum acquire the ability to become infected with wtMV, these
data suggest that PVRL4 is an authentic epithelial cell receptor for
MV. MDCK cells, which were originally derived from dog
kidneys, also express PVRL4 on their surface. However, they are
not susceptible to wtMV infections, suggesting that differences in
the protein sequence of canine PVRL4 may reduce its ability to
serve as a receptor for wtMV. In all epithelia derived cell lines that
were tested, the presence of cell surface PVRL4 correlates with
their ability to be infected with wtMV.
The epithelial cell receptor is expressed on the apical and
basolateral surfaces of polarized adenocarcinoma cells
Many of the epithelial cell lines susceptible to wtMV have
previously been shown to be polarized. In order to determine
whether the putative epithelial receptor was situated on either the
apical or basal surface of the cellular monolayer, cells were
cultivated on polyester Transwell filter supports (0.4 mm pore size,
24 mm diameter). Cells were ascertained to be polarized by
measuring their transepitheilal electrical resistance (TEER). In
uninfected cells the TEER maximized at 1200 V-cm
2 at 4 days
and remained constant for 10 days from the time of initial culture.
Confluent cell monolayers were infected from either the apical or
basolateral side with IC323-EGFP wtMV and visualized by
fluorescence microscopy. The virus preferentially infected both
MCF7 and NCI-H358 cells via the apical route, although
basolateral infection was seen at later times post infection
(Figure 5A and 5B). To control for the ability of the virus to
traverse through the membrane pores, CHO cells stably
expressing PVRL4 were inoculated with wtMV from either the
apical or basolateral side of the transwell filter (Figure 5C). These
non-polarized cells express PVRL4 on both their apical and
basolateral surfaces. A lag in MV replication revealed by EGFP
expression was observed in the basolateral infections compared to
the apical infections. These data suggest that the Transwell
membrane may play a role in hindering the ability of MV to infect
cells via the basolateral surface. To increase the efficiency of
basolateral infections, we prolonged viral adsorption times to 4 hr
and decreased the stringency of washing non-adsorbed virus from
the cells, but this had no effect. We concluded that wtMV could
infect polarized MCF7 and NCI-H358 cells via either the apical or
basolateral route, suggesting that PVRL4 is expressed on both cell
surfaces.
To investigate the expression pattern of PVRL4 on adenocar-
cinoma cell lines, susceptible (MCF7 and NCI-H358 cells) and
non-susceptible (MDA-MB-231 and A549) cells were stained with
PVRL4 antibodies (Figure 6A and 6B). PVRL4 expression was
localized to the junctions between cells in susceptible cells only.
Upon further examination, PVRL4 appeared to be expressed on
both the apical and basolateral side of MCF7 and NCI-H358 cells
(Figure 6C & 6D). Surface biotinylation of MCF7 cells also
confirmed that PVRL4 was expressed on both the apical and basal
surfaces (Figure 6D). Membrane proteins were biotinylated on
either the apical or basolateral sides of the cell, precipitated with
Neutravidin, resolved by SDS-PAGE, and PVRL4 was detected
on immunoblots with specific antibodies. The data confirmed that
PVRL4 was expressed on both the apical and basolateral surfaces
of adenocarcinoma cell, although the band intensities did not
appear to be quantitative. Apical labeling of PVRL4 did not
appear to be as efficient as that of the basolateral protein. This
may be due to cell surface factors such as mucous formation or
glycocalyx, and this observation will require further investigation.
However, the biotin labeling studies do confirm qualitatively that
PVRL4 is situated on both surfaces of the cell.
PVRL4 is also localized to the cellular junctions of normal and
cancerous tissues. The protein is abundantly expressed in most
lung adenocarcinomas, some lung squamous carcinomas, an NIC-
H358 xenograft from mice, and placenta microvilli. Reactive
pneumocytes derived from normal lungs and tonsils exhibited
lower levels of expression (Figure S5 in Text S1). Recent reports
from The Human Protein Atlas Project (www.proteinatlas.org)
have shown that PVRL4 is expressed abundantly in placental
trophoblasts, glandular cells of the stomach, and adenocarcinomas
of the lung, breast, and ovary. According to this study, moderate
amounts of this protein are expressed in the epithelium of tonsils,
Common Genes
Up-regulated in
Breast & Lung Cells
% Gene
Up- Regulation
in Breast Cells
% Gene
Up- Regulation
in Lung Cells
Common Genes
Up-regulated in
Breast, Lung, SAEC
% Gene
Up- Regulation
in SAEC
PCDHB13 23.84833 85.86242
See also Table S1.
*Primary screening of candidate receptors with cDNA expression vectors following comparison of lung and breast cancer cell lines0.
**Secondary screening of candidate receptors with cDNA expression vectors following comparison of lung, breast, and SAEC cell lines.
doi:10.1371/journal.ppat.1002240.t002
Table 2. Cont.
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nasopharynx. Smaller amounts are expressed in the lung
macrophages and neuronal cells of the cerebral cortex.
siRNA directed against PVRL4 blocks infections by wtMV
To investigate whether PVRL4 was a bona fide receptor for
wtMV, siRNA against PVRL4 was used in the susceptible MCF7
and NCI-H358 cell lines. A pool of siRNA specific for PVRL4 or a
scrambled siRNA control were transfected into MCF7 or NCI-
H358 cells for 72 hrs. FACS analysis demonstrated that PVRL4
surface expression was effectively reduced following siRNA
knockdown (Figure 7A). The cells were subsequently infected
with IC323-EGFP wtMV and fluorescence was monitored after a
further 48 hr incubation, at which point virus was harvested.
Scrambled siRNA did not inhibit MV infections (Figures 7B, 7C)
while PVRL4 siRNA treatment clearly blocked the fluorescence
produced by MV. Virus released from siRNA-treated MCF7 and
NCI-H358 cells was subsequently quantified on Vero/SLAM
cells. A decrease in approximately 1–2 logs was consistently seen
when PVRL4 expression was knocked down prior to MV
infection. The siRNA inhibition experiments conclusively demon-
strated that unrestricted PVRL4 surface expression was essential
for wtMV infection.
Antibodies specific for human PVRL4 inhibit wtMV
infection in MCF7 cells
MCF7 cells grown on glass coverslips were incubated with
10 mg/ml non-immune goat IgG (Figure 8A and 8B) or goat anti-
PVRL4 (Figure 8C and 8D) for 30 min prior to, and during 1 hr
adsorption with IC323-EGFP MV via the apical surface.
Fluorescence and syncytia formation due to viral infection at
48 hrs was inhibited by the PVRL4 antibody treatment. To
determine whether antibodies directed against PVRL4 also
blocked infection by the basolateral route, MCF7 cells were
grown on Transwell permeable filter supports as described in
Figure 5. Cells were incubated on the apical (Figure 8E, 8F, 8G,
and 8H) or basal (Figue 8I, 8J, 8K, and 8L) surfaces with
antibodies directed against human PVRL4 or non-immune
antibodies for 30 min and subsequently inoculated with IC323-
EGFP MV (m.o.i. 10) for 4 hrs in the presence of antibody.
Infections proceeded for 72 hrs and cells were viewed by
fluorescence and bright field microscopy. Interaction of goat
polyclonal antibodies with PVRL4 blocked MV infection of
MCF7 cells when applied via either the apical or basal routes. This
inhibition indicated that MV can infect adenocarcinoma cells in a
PVRL4-dependent manner by either the apical or basolateral
route. The antibody inhibition provided further corroboration of
the preceding RNA interference studies directed against PVRL4.
PVRL4 acts as an attachment receptor for wtMV
To assess the ability of MV to bind PVRL4, CHOpgsA745 cells,
which lack heparan and chondroitin sulfate on their surface, were
engineered to stably express PVRL4 (CHO-PVRL4). Flow
cytometry with a monoclonal antibody specific for human PVRL4
indicated extensive surface expression of this protein on the CHO-
PVRL4 cells (Figure 9A, inset). CHO and CHO-PVRL4 cells
were incubated with wtMV in the presence of blocking antibodies
to PVRL4 (gPVRL4) or an isotype control (gIgG). Virus binding
was detected using a monoclonal antibody directed against the H
protein and an alexa fluor 488-conjugated goat anti-mouse
secondary antibody. Interestingly, background wtMV binding
was consistently ,15–30% in CHO cells irrespective of whether
the blocking antibody to PVRL4 was present (Figure 4A, CHO;
Figure 9B). In CHO-PVRL4 expressing cells, however, there was
a shift in the histogram peak in the gIgG + wtMV treatment,
indicating that wtMV had bound to these cells (Figure 9A). When
blocking antibodies to PVRL4 were present, the MV binding
decreased to background levels seen in the CHO cells (Figure 9B,
compare CHO-huPVRL4 gIgG Ab to gPVRL4 Ab) irrespective of
the MOI used. These data suggest that PVRL4 is an attachment
receptor for wtMV. The CHO-PVRL4 cells were subsequently
infected with various multiplicities of infection (MOI) of IC323-
EGFP wtMV for 48 h (Figure 9C). An increase in the level of
wtMV replication was detected with increasing amounts of MV in
the CHO-PVRL4 cells, but only background infections were seen
in the CHO cells lacking PVRL4. These results clearly establish
PVRL4 as an attachment receptor for MV.
Mouse PVRL4 functions less efficiently as a receptor for
MV than the human homologue
Mouse PVRL4 shares 92% amino acid sequence identity with
the human homologue (Figure S6 in Text S1). Expression vectors
containing the cDNA sequences for the Myc-DDK tagged versions
of human and mouse PVRL4 were transfected into COS-1 cells.
These cells were infected with IC323-EGFP wtMV and viewed by
fluorescence microscopy at 48 hrs post-infection (Figure 10A).
COS-1 cells expressing mouse PVRL4 were less susceptible to
infection by IC323-EGFP wtMV and produced smaller and fewer
syncytia than cells transfected with the human homologue
(Figure 10A). Virus released from the infected cells was compared
using quantitative plaque assays. As expected, COS-1 cells
transfected with mouse PVRL4 produced less MV than cells
transfected with the human PVRL4 homologue (Figure 10B).
These results were consistent over the course of 4 separate experi-
ments. Expression levels of mouse PVRL4 were compared to
human PVRL4 by immunoblot analysis with antibodies specific
for the Myc-DDK tags and were found to be similar. Surface
expression of mouse and human forms of PVRL4 were also
comparable (Figure 10C). Finally, MV proteins were synthesized
in the infected cells as shown by a Western immunoblot using
antibodies directed against the matrix (M) protein (Figure 10D).
Other MV strains can also use PVRL4 (Nectin 4) as a
receptor
Other strains of MV were tested for their ability to use PVRL4
as a cellular receptor. The Edmonston-EGFP vaccine strain
(Figure S7A and S7B in Text S1), WTF-EGFP wtMV (Figure S7C
and S7D in Text S1), and Montefiore 89 wtMV (Figure S7E and
S7F in Text S1), were inoculated onto cells transfected with the
human PVRL4 expression vector. In the case of Edmonston-
Figure 3. Nectins closely related to PVRL4 cannot function as receptors for wtMV. COS-1 cells were transfected with expression vectors
encoding DDK-tagged versions of PVR, PVRL1, PVRL2, PVRL3, and PVRL4. Control cells were transfected with empty plasmid. After 36 hrs, the
transfected cells were infected with IC323-EGFP wtMV and incubated a further 48 hrs. (A) Cells were viewed by fluorescence and phase contrast
microscopy. Scale bar =200 mm. (B) Virus released from the infected cells was quantified by plaque assay. Data are expressed as the mean of three
independent experiments, with error bars showing the SEM. (C) Total cell expression of the transfected proteins was evaluated by Western
immunoblots using antibodies directed against the DDK(Flag). (D) Viral proteins were synthesized in PVRL4 transfected cells following MV infectiona s
shown by Western immunoblot using an antibody specific for the viral matrix (M) protein.
doi:10.1371/journal.ppat.1002240.g003
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which are known to be deleted for the critical SCR1 domain of
CD46, and are normally resistant to infection by vaccine strains of
MV [53]. The WTF-EGFP wtMV and Montefiore 89 wtMV
cannot use CD46 as a receptor, and were inoculated onto HeLa
and 293 HEK cells, respectively, that expressed PVRL4. In both
experiments, expression of PVRL4 converted the non-susceptible
OMK and COS-1 cells to a MV susceptible phenotype. Cells
infected with Montefiore 89 wtMV were fixed with paraformal-
dehyde and incubated with antibodies specific for MV proteins (H,
M). Infections were detected by EGFP fluorescence or anti-
measles H, M immune fluorescence microscopy (Figure S7 in Text
S1).
PVRL4 surface expression is down regulated in MCF7
cells following wtMV infection
An important aspect of MV infection is the down regulation of
CD46 and SLAM from the cell surface following MV-H
expression [56–60] To determine whether PVRL4 expression
was down regulated in a similar manner, FACS analysis of PVRL4
surface expression was performed at 48 h post infection. Alexa
fluor conjugated 647 secondary antibodies were used to detect
SLAM and PVRL4 surface expression (Figure 11). SLAM surface
expression on B95a cells was down regulated following infection
with IC323-EGFP wtMV (Figure 11A) in the presence of the
fusion inhibitory peptide, as expected. Similarly, IC323-EGFP
wtMV infection caused a decrease in the level of PVRL4 surface
expression on MCF7 cells (Figure 11B). The level of MV
replication was assayed by the presence of GFP positive cells
(Figure 11, inset). At 48 h post infection more GFP positive cells
were seen in the MV-infected B95a cells compared to the MV-
infected MCF7 cells. Taken together, these data suggest that, like
SLAM (CD150), PVRL4 is also down regulated following wtMV
infection.
Discussion
PVRL4 (Nectin 4) was demonstrated to be an epithelial receptor
for MV. This protein is a member of the poliovirus receptor-like
proteins (PVRLs) that are adhesion receptors of the immunoglob-
ulin superfamily [61]. It is a 510-amino acid transmembrane
protein with a predicted molecular mass of 55.5 kDa which
migrates with a mass of 66 kDa on SDS polyacrylamide gels due
to N-glycosylation. PVRL4 is an embryonic protein which has
recently been shown to be a tumor cell marker for lung, breast,
and ovarian adenocarcinomas [62–64]. Like other nectins,
PVRL4 is normally localized to the adherins junctions together
with the cadherins. PVRL4 interacts with itself and the V domain
of PVRL1, but not with other members of the same molecular
family. Its cytoplasmic tail associates with the intracellular actin-
binding protein, afadin [65]. In humans it is expressed abundantly
in the placenta and weakly in the trachea. However, in the adult
mouse, PVRL4 transcripts were also found in the brain, lung, and
testis [61]. More recently, The Human Protein Atlas Project
(www.proteinatlas.org) has reported that PVRL4 is expressed
abundantly in placental trophoblasts, glandular cells of the
stomach, and adenocarcinomas of the lung, breast, and ovary.
Moderate amounts of this protein appear to be expressed in the
epithelial cells of tonsils, oral mucosa, esophagus, and the
columnar epithelial cells of the nasopharynx and trachea. Smaller
amounts are expressed in the lung macrophages and neuronal cells
of the cerebral cortex.
The nectins can also function as entry receptors for several other
viruses. PVR (CD155) is the prototype member of the family and
was originally shown to be the receptor for poliovirus [66]. PVRL1
(Nectin 1) serves as an entry receptor for herpes simplex virus
(HSV). It is the major HSV receptor and mediates entry of all
HSV-1 and HSV-2 strains as well as animal alphaherpesviruses
[48]. PVRL2 (Nectin 2) can also function as an entry factor for
some herpesviruses [67]. Alternatively, HSV can use another
receptor of the TNF family called herpes virus entry molecule
(HVEM). The fact that HSV-1 and HSV-2 use multiple receptors
for cell entry appears to enable the virus to enter different cell
types [68]. This also appears to be the case with MV. The
expression of Nectin 1 on the cell surface of tumors is also a
predictor of oncolytic sensitivity to HSV in potential cancer
therapy [69]. Tight junction proteins can also serve as receptors
for some viruses. For example, occludin is a major component of
tight junctions that is used by hepatitis C virus [50] and group B
coxsackievirus as an entry factor [49]. However, occludin shRNA
experiments in MCF7 cells had no effect upon MV infectivity
(data not shown).
The actual role of epithelial cells in MV infections has been
controversial in light of recent experiments with macaques and
SLAM transgenic mice. Alveolar macrophages, dendritic cells, and
activated lymphocytes have recently been reported to be primary
targets for IC323-EGFP wtMV and rMV
KS-EGFP strains, and
there was only limited infection of epithelial cells in the studies
with macaques over 5 to 9 days infection [32–35]. Although
lymphocytes and dendritic cells may be the major target and
reservoir, virus has also been reported in the squamous stratified
epithelium of the tongue and buccal mucosa and in the ciliated
epithelium of the trachea at the peak of infection [32]. It has been
proposed that immune cells transmit MV to airway epithelial cells
via a receptor on their basolateral surface and that these infected
cells release virus from their apical cell surface to further infection
and spread [33,42]. It is possible that infected lymphocytes,
expressing H and F proteins on their surface, attach to PVRL4
expressing epithelial cells to facilitate cell to cell spread of MV and
syncytia formation late in infection. Again infected epithelial cells
appeared at later times of infection than infected lymphocytes and
dendritic cells [70]. When a mutant MV that was blind to the
epithelial receptor was used to inoculate macaques, clinical
symptoms of measles were observed, but no virus was shed into
the airways of these animals [33]. This observation has led the
researchers to conclude that the infection of epithelial cells
occurred later in the disease, and was important for aerosol
transmission of the virus.
We were initially surprised to observe that wtMV could infect
adenocarcinoma cell lines from the apical surface in our Transwell
filter assays. However, this finding may not be unreasonable since
we were working with cancer cells where PVRL4 is highly
upregulated, and it is expressed on both apical and basolateral cell
surfaces. We have carefully considered the possibility that MV
Figure 4. Flow cytometry analysis reveals PVRL4 (Nectin 4) surface expression on cells susceptible for wild type MV infections. (A)
Susceptible cell lines were incubated with a phycoerythrin-conjugated mouse monoclonal antibody that was specific for human PVRL4 (red
histogram) or a PE-conjugated mouse IgG2a control antibody (shaded histogram). Cells were washed and analyzed with a Beckman-Coulter ADP
Cyan flow cytometer. The Y-axis represents cell counts and the X-axis represents fluorescence intensity. (B) Non-susceptible cell lines were analyzed as
described for Panel A.
doi:10.1371/journal.ppat.1002240.g004
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PLoS Pathogens | www.plospathogens.org 12 August 2011 | Volume 7 | Issue 8 | e1002240Figure 5. MV infects polarized adenocarinoma cells via either the apical or basolateral surfaces. Wild type IC323 MV infects (A) MCF7
(breast), (B) NCI-H358 (lung) adenocarcinoma and (C) CHO-PVRL4 cell lines via the apical and basolateral surface in Transwell filter assays. Cells were
cultivated in Transwell permeable filter supports at a density of 7.0610
5 cells per Transwell filter (24 mm diameter) for 4 days (MCF7 & NCI-H358) or 2
days (CHO-PVRL4). Cells were then infected from either the apical or basolateral side with IC323-EGFP wtMV. At various times post infection
fluorescent images were captured. Scale bar=500 mm.
doi:10.1371/journal.ppat.1002240.g005
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totally relevant to understanding viral pathogenesis in the airways
of the normal host. It has previously been reported that MV
preferentially infects differentiated primary epithelial cells via the
basolateral route, which is consistent with the location of PVRL4
at the adherens junctions of normal cells [33,34,40]. Foci of
infected cells derived from basolateral infections of primary
epithelial cells did not appear to fuse and produce syncytia. This
Figure 6. PVRL4 is localized to both the apical and basolateral surfaces in MCF7 and NCI-H358 cancer cells. (A) Breast (MCF7 and MDA-
MB-231) and (B) lung (NCI-H358 and A549) cancer cell lines were grown to confluence on glass coverslips and then fixed with paraformaldehye,
permeabilzed, and stained with goat-anti human PVRL4 antibodies (yellow). Nuclei were visualized with TO-PRO-3 nuclear stain (cyan). Images were
captured on a Zeiss upright confocal microscope and analyzed using Zen 2008 image capture software (Zeiss). Scale bar =20 mm. (C) Z-sections of
MCF7 and NCI-H358 cells stained with PVRL4 (yellow) and TO-PRO-3 (cyan). PVRL4 is localized to both the apical [A] and basolateral [B] surfaces of
these cells. White arrowheads indicate the apical expression of PVRL4. (D) Surface biotinylation of MCF7 cells. MCF7 cells were grown for 96 h on
transwell filters (24 mm diameter). The cells were incubated with NHS-biotin from either the apical (lanes A) or basolateral (lanes B) side. After lysis,
surface proteins were immunoprecipitated with Neutravidin, and immunocomplexes were subjected to SDS-PAGE and Western blot for PVRL4.
Glyceraldehyde 3-phosphate (GAPDH) was used as a loading control.
doi:10.1371/journal.ppat.1002240.g006
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PLoS Pathogens | www.plospathogens.org 14 August 2011 | Volume 7 | Issue 8 | e1002240Figure 7. siRNA specific for human PVRL4 inhibits wtMV infections. MCF7 and NCI-H358 cells were transfected with a scrambled
oligonucleotide control (ctrl siRNA) or a siRNA pool specific for PVRL4 (PVRL4 siRNA). The transfected cells were incubated with IC323-EGFP wtMV and
images were captured 48 hr post infection. (A) PVRL4 surface expression was detected with a phycoerythrin conjugated PVRL4 antibody following
gene knockdown with control siRNA (red line) or PVRL4 siRNA (blue line). (B) PVRL4 siRNA-treated MCF7 and NCI-H358 cells showed less GFP
expression compared to ctrl siRNA-treated cells. (C) PVRL4 knockdown results in a decrease in wtMV titres in MCF7 and NCI-H358 cells. Forty-eight
hours post infection, cells were harvested and TCID50 virus titrations were performed on Vero-SLAM cells. Data are the means from three independent
experiments, and error bars represent the SEM. Scale bar=100 mm.
doi:10.1371/journal.ppat.1002240.g007
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convert primary human SAEC grown in serum free to a MV
susceptible phenotype by culturing them in 2% fetal calf serum.
Flow cytometry indicated that little PVRL4 was produced on
SAEC grown in serum free media, but the nectin was induced
following transfer to serum containing media. PVRL4 may be
expressed at higher levels on the apical surface during phases of
rapid growth. In support of this, PVRL4 is highly expressed during
embryogenesis [61]. Upon revisiting the literature, we discovered
that laboratories looking at basolateral infections of polarized
primary human epithelial cell monolayers were waiting from 3–7
days post infection in order to see infected cell foci, and that apical
infection of susceptible cancer cell lines was more efficient. This
was consistent with our observations in Figures 5 and 8. In our
hands, both MCF7 and NCI-H358 cells produced syncytia when
infected via the basolateral route, although apical infection was
much more efficient. Similar results were reported by Tahara et al.
who showed that polarized CaCo2 and HT-29 cells were
preferentially infected via the apical surface [41]. They also
commented in their results section that the virus infected the
basolateral side of the polarized monolayer much less efficiently
than the apical side. Other investigators also obtained similar
results using a laboratory strain of MV to infect CaCo2 cells [40].
However, when they infected primary human airway epithelia via
the basolateral surface, they saw more virus replication compared
to infection of the apical side. Mutations in the putative epithelial
receptor binding region of MV H protein, to produce an epithelial
receptor blind virus, blocked basolateral infection of primary cells
as well as apical infection of lung adenocarcinoma cell lines,
indicating that the same receptor is probably used in each case
[33,41].
Other laboratories have shown that PVRL4 (Nectin 4) is up-
regulated on breast, lung, and ovarian cancer tumors and cell lines
[62,63,71]. We extended this observation to colon carcinoma cell
lines including DLD-1, HT29, and LoVo cells. There are anecdotal
reports in the literature where natural MV infections were shown to
reverse cases of Burkitt’s lymphoma and Hodgkin’s disease [72–75].
Given that these tumors express SLAM/CD150, one can presume
thatwtMVinfectedthetumorsand triggeredimmuneattackagainst
them. Vaccine strains of MV have previously been engineered to
recognize cancer cells by artificially manipulating the H receptor
binding protein [12]. Clinical trials are currently in progress at the
Mayo Clinic (Rochester, MN) for ovarian cancer, pancreatic
cancer, glioblastoma, medulloblastoma, and multiple myeloma
[12]. It may be possible that a natural tropism of MV for lung,
breast, colon, bladder, and ovarian adenocarcinomas can also be
exploited for future oncolytic therapies. The use of SLAM/CD46
blind MVthat retained the ability tobindPVRL4could constitute a
potentialtherapeuticvaccineagainstadenocarcinoma.Safetyissues,
background infection, and the effect of pre-existing antibodies from
MMR vaccination will obviously have to be addressed before
human clinical trials could even be considered.
This study identifies PVRL4 (Nectin 4) as an epithelial receptor
for MV. PVRL4 is expressed at low to moderate levels in normal
tissues but is highly up-regulated on the surfaces of adenocarci-
noma cells. The interaction is highly specific, since MV does not
recognize other members of the PVRL family and prefers the
human receptor over homologues in the mouse. Further
experiments with differentiated primary epithelial cells in culture
and the use of human epithelial explants will be required to
validate the role of PVRL4 in infections of normal epithelial cells
and establish its importance in measles pathogenesis. These studies
are currently underway in our laboratory.
Materials and Methods
Antibodies
M75 and B97 monoclonal antibodies, which neutralize CD46
binding to MV, were obtained from Seikugaku (Tokyo, Japan)
and Dr. J. Schneider-Schaullies (Wurzburg, Germany), respec-
tively. IPO-3 and A12 monoclonal antibodies, which inhibit
CD150 binding to MV, were purchased from AbCam (Cam-
bridge, MA). PE-conjugated mouse anti-human CD150/SLAM
(clone A12) and PE-conjugated mouse IgG1 kappa isotype
control (clone MOPC-21) were from BD Biosciences. Unconju-
gated mouse anti-human nectin-4 (MAB2659), PE-conjugated
mouse anti-human nectin-4 monoclonal (FAB2659P), PE-conju-
gated mouse IgG2B isotype control (IC0041P), goat polyclonal
anti-human PVRL4 (AF2659), and control goat (AB-108-C)
antibodies came from R&D Systems (Minneapolis, MN).
Monoclonal mouse anti-V5 (Sigma, clone V5-10) was used to
detect V5 tagged proteins synthesized from the pcDNA3.2
DEST/V5 expression vector. The anti-Flag antibody (Sigma) was
used to detect DYKDDDDK tagged proteins expressed from the
pCMV6 entry vector.
Cell culture and virus infections
Human primary small airway epithelial cells (SAEC) were
obtained from Lonza Walkersville Inc., (Walkersville, MD).
Marmoset SAEC were prepared by the custom service division
of Lonza Walkersville Inc. Vero, B95a, OMK, HeLa, LoVo,
Huh7, HepG2, Hep3B, and CHOpgsA745 cells, were purchased
from the American Type Culture Collection (Manassas, VA).
NCI-H125, NCI-H157, NCI-H460, SBC-3, NCI-H661, NCI-
H520, RVH6847, NCI-226, MGH-7, MGH-24, and NCI-H358
cells came from Dr. Ming-Sound Tsao (Ontario Cancer Institute,
Toronto, Canada). MDA-MB-468, MDA-MB-231, MCF7,
T47D, HT-29, T84, HCT116, HS766T, DLD-1, and MDCK
cells were acquired from Drs. David Hoskin and Craig
McCormick (Dalhousie University, Halifax, Canada). The Ed-
monston vaccine/laboratory strain of MV was originally obtained
from Dr. Erling Norrby (Karolinska Institute, Stockholm,
Sweden). The recombinant Ichinoise-B 323 (IC323) wild type
isolate expressing EGFP reporter gene (IC323-EGFP wtMV) and
a recombinant Edmonston MV containing a WTF H protein (in
place of the H protein of the vaccine strain), Edmonston-EGFP
MV, SLAM blind-EGFP and CD46 blind-EGFP recombinant
viruses were obtained from Dr. Roberto Cattaneo [33,52]. The
Figure 8. Antibodies specific for human PVRL4 inhibit wtMV infection in MCF7 cells. MCF7 cells grown on glass coverslips were incubated
with 10 mg/ml goat IgG (A,B) or goat anti-PVRL4 (C,D) for 30 min prior to, and during 1 hr adsorption with IC323-EGFP MV via the apical surface.
Fluorescence and syncytia formation due to viral infection at 48 hrs was inhibited by the PVRL4 antibody treatment. To determine whether PVRL4
antibodies would also inhibit MV infections via the basolateral route, MCF7 cells were grown on Transwell permeable filter supports as described in
Figure 5. Cells were incubated with 25 mg/ml goat IgG on the apical (E,F,G,H) or basal (I,J,K,L) surface with antibodies specific for human PVRL4 or
non-immune antibodies (IgG) for 30 min. Cells were subsequently inoculated with IC323-EGFP MV (MOI=10) for 4 hrs, also in the presence of
antibody. Infections were allowed to proceed for 72 hrs and cells were viewed by fluorescence and bright field microscopy. The interaction of goat
polyclonal antibodies with PVRL4 blocked MV infection of MCF7 cells via either the apical or basal routes. Scale bar =100 mm.
doi:10.1371/journal.ppat.1002240.g008
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PLoS Pathogens | www.plospathogens.org 17 August 2011 | Volume 7 | Issue 8 | e1002240Figure 9. IC323 wtMV binds to cells that stably express human PVRL4. CHO or CHO stably expressing human PVRL4 (CHO-huPVRL4) were
incubated with either 10 or 25 PFU/cell of IC323-EGFP wtMV in the presence of isotype (gIgG Ab) or blocking antibodies against PVRL4 (gPVRL4 Ab)
for 1.5 h. Cells were incubated with a MV anti-H primary antibody followed by an anti-mouse alexa fluor 488 conjugated secondary antibody to
detect MV-bound cells. (A) Binding of IC323 wtMV to cells stably expressing PVRL4 was detected by FACS. CHO and CHO-huPVRL4 cells were
inoculated with MV in the presence of blocking antibody against PVRL4 (gPVRL4, red line) or an isotype control (gIgG, blue line), washed, and
incubated with anti-MV hemagglutinin antibody or an isotype matched control antibody (green line). Cells incubated in the absence of virus (Mock,
filled histogram) were stained with anti-MV hemagglutinin antibody. Bound MV-specific primary antibody was detected with alexa fluor 488-
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Spigland and Amy Fox (Montefiore Medical Center, Bronx, NY).
CD46 diagnostic RT-PCR and agarose gel electrophoresis
Total RNA was extracted from HeLa, marmoset kidney
NZP60, and marmoset SAEC using TRIzol (Invitrogen). First
strand cDNA was prepared with a SuperScript III kit (Invitrogen).
PCR was performed with conserved diagnostic CD46 primers
spanning the SCR1 coding region of cDNA from the different cell
types [59oligo: gccgccgcgagtgtccctttccttc; 39oligo: cactttggaactgggg-
gatcccaag]. PCR amplification was done using PFUultra II fusion
HS polymerase (Stratagene). A 50 ml reaction volume was initially
heated for 2 min at 95u, processed through 30 cycles of sequential
temperatures of 95u (30 sec), 58u (30 sec), 72u (30 sec) and finally
incubated for 10 min at 72u, using an Applied Biosystems
Geneamp 9600 PCR machine. Samples were stored at 4u, prior
to electrophoresis at 120 V on 0.9% agarose gels containing
ethidium bromide. The PCR product derived from full length
human CD46 cDNA was 834 bp and that from marmoset CD46
cDNA was 645 bp, as predicted from the sequences in the NCBI
genebank (NM_002389.4 and U87917).
Microarray analysis
Primary SAEC (Lonza) were cultured in a 6-well culture plate in
DMEM with and without 2% FCS for 22 hrs. Cell lines were
grown in 75 cm
2 T-flasks containing DMEM and 10% FCS.
Extraction of total RNA was performed using a Qiagen RNeasy
Kit (Qiagen). Analysis for mRNA transcripts was performed using
the Affymetrix Human Gene ST 1.0 Array at The Centre for
Applied Genomics located at The Hospital for Sick Children in
Toronto, Canada. cDNA’s from SAEC, susceptible (MCF7,
MDA-MB-468, T-47D, NCI-H125, NCI-H358, and MGH-24)
and non-susceptible (A549, MDA-MB-231) cell lines were biotin
labeled, hybridized to the microarray chip, washed, and stained
with streptavidin-PE. Normalized probe set data was analyzed
with the Affymetrix Expression Console 1.1 software. Microarray
data was deposited in the NCBI GEO database (accession
#GSE26636). Further details are provided in Supporting
Information.
Plasmid transfection of candidate epithelial receptors
A human plasma membrane open reading frame gene
collection (HS5016) was obtained from Open Biosystems (Hunts-
ville, AL). The genes contained within pDONR223 entry vectors
were introduced into the Gateway pcDNA3.2/V5-Dest mamma-
lian expression plasmid through recombination using the LR
Clonase II system (Invitrogen). These genes contained a V5 tag.
Genes which were not contained in the Open Biosystems
Membrane Protein collection were purchased from Origene
Systems (Rockville, MD) and contained a DDK (Flag) tag.
Expression plasmids were introduced into non-susceptible cells
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer. Empty vector (pcDNA3.2-V5/Dest or pCMV6 DEST) as
well as EGFP and SLAM expressing plasmids were included as
controls. At 36–48 hrs post transfection, cells were inoculated with
IC323-EGFP wtMV in Opti-MEM media (Invitrogen) at an m.o.i.
of 10 for 2 hrs at 37uC. The inoculums were replaced with
Dulbecco’s minimum essential media containing 2% fetal calf
serum. After 48 hrs, infected cells were visualized by phase
contrast and fluorescence microscopy.
To assess protein expression of the candidate receptors, cell
monolayers were lysed in radioimmunoprecipitation (RIPA) buffer
(50 mm Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycho-
late, 150 mM sodium chloride, 1 mM ethylenediaminetetraacetic
acid, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 2 mM dithiothreitol, 1x protease
inhibitor cocktail [Roche]) for 15 min on ice. The lysate was
centrifuged at 13,000 x g for 15 min at 4uC, and protein quanti-
fication was performed with the Bradford assay kit (Thermo
Scientific). SDS-PAGE and Western immunoblotting was carried
out using antibodies against DDK and V5 to detect expression of
the candidate membrane receptors.
Flow cytometry
Cells were grown to confluence in 10 cm
2 dishes, washed twice
in cold PBS, and harvested in non-enzymatic cell dissociation
buffer (Sigma). 250,000 cells were blocked with 2.5 mg of normal
human IgG (R&D Systems) for 10 minutes on ice followed by the
addition of 10 ml of either PE-conjugated PVRL4 (R&D Systems
FAB2659P) or PE-conjugated mouse IgG2B isotype control (R&D
Systems IC0041P) antibodies for 45 min on ice. Cells were washed
twice in PBS containing 1% BSA, 5 mM EDTA, and 0.1%
sodium azide and then fixed in 1% paraformaldehyde. Samples
were run on a Cyan ADP Flow Cytometer (Beckman Coulter) and
data were processed using FCS Express (De Novo Software).
Unconjugated SLAM and mouse anti-human PVRL4 antibodies
were used in the receptor down regulation experiments. Secondary
antibodies conjugated to Alexa Fluor 647 were used to detect
surface expression of SLAM and PVRL4 using the FL8 channel
on the Cyan ADP Flow Cytometer.
Infection of the basolateral and apical epithelial cell
surface with MV
MCF7, NCI-H358, and CHO-PVRL4 cells were seeded onto
Transwell permeable filter supports (Corning Inc., 0.4 mmp o r e
size, 24 mm diameter) at a density of 7.0610
5 cells per well for 4
days (MCF7 & NCI-H358) or 2 days (CHO-PVRL4). Polariza-
tion of MCF7 cells was verified by measuring transepithelial
electrical resistance (TEER) with a Millipore-ERS Voltohmmeter
equipped with STX electrodes (Millipore, Billerica MA). An
impedence of greater than 500 V-cm
2 indicated that a cell line
was polarized. To infect the apical surface, 10 PFU/cell of
IC323-EGFP wtMV was added to the upper chamber of the
transwell filter and allowed to adsorb for 2 h. To infect the
basolateral surface, filter inserts were inverted and the virus was
adsorbed for 2 h. The virus innoculum was subsequently
removed from the apical or basolateral surface and the
membranes were treated with citrate buffer to inactivate any
non-internalized virus. The transwell filters were then returned to
their normal orientation. Infected cells were viewed by fluores-
cence and phase contrast microscopy using a Leica DMI4000B
inverted microscope (Leica Microsystems).
conjugated goat anti-mouse secondary antibody. The relative fluorescence intensity was measured on a Cyan ADP Flow Cytometer. Inset: Receptor
expression was detected with a PE-conjugated PVRL4 antibody (red histogram) or isotype control (filled histogram). (B) Quantification of MV binding
to CHO cells expressing huPVRL4 in the presence of blocking antibody to PVRL4 (gPVRL4 Ab). The perecentage of MV-bound cells compared to mock
cells was determined using FCS express (De Novo software). Data are expressed as the mean from three independent experiments, with error bars
showing the SEM. (C) Infection of CHO and CHO-huPVRL4 cells with varying multiplicities of infection using IC323-EGFP wtMV. Images were captured
48 h post infection. Scale bar =500 mm.
doi:10.1371/journal.ppat.1002240.g009
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Cells grown on poly-D-lysine (Sigma) coated coverslips were
fixed in 4% paraformaldehyde (10 min) and permeabilzed with
0.1% Triton X-100 in PBS (10 min). PVRL4 was detected by
incubating the cells with goat anti-human PVRL4 (R&D Systems
AF2659) at 7.5 mg/ml in PBS containing 5% FCS for 45 min at
room temperature. Cells were subsequently stained with fluor-
ophore-conjugated secondary antibodies for 30 min at room
temperature. Nuclear DNA was stained (20 min) with TO-PRO-3
stain (Invitrogen). Cells were mounted with fluorescent mounting
medium and images were acquired with ZEN 2008 imaging
software on a Zeiss LSM 510 upright laser scanning confocal
microscope. Images were captured with a 100x Plan APOC-
HRMOAT (1.4NA) objective lens and processed using ZEN 2009
light and Adobe Photoshop CS3 using only linear adjustments.
Surface biotinylation
Levels of PVRL4 on the cell surface of MCF7 cells were
determined by surface biotinylation. Cells were seeded onto transwell
filters (0.4 mm pore size, 24 mm diameter) at a density of 5.0610
5
cells per filter. Five days post seeding, cells were washed either the
apical or basolateral side of the membrane was incubated for 1 hour
with PBS containing 2 mM S-NHS-biotin (Thermo Scientific) at
4uC, while 0.1 M glycine was added to the opposite side of the
membrane. After washing with 0.1 M glycine, filter membranes were
cut and cells were lysed in RIPA buffer Cell lysates were clarified by
centrifugation at 21 000 x g and biotinyalted surface proteins were
immunoprecipitated with agarose-conjugated NeutrAvidin (Thermo
Scientific). Following SDS-PAGE and immunoblotting onto poly-
vinylidene fluoride (PVDF) (Millipore), proteins were detected with
goat anti-human PVRL4 antibodies (R&D Systems). Secondary
antibodies were conjugated to horseradish peroxidase and visualized
by chemiluminescence. Thirty micrograms of total whole cell lysate
was run and blotted with anti-human PVRL4 antibodies and anti-
GAPDH antibodies to control for protein loading.
siRNA inhibition
siRNA duplexes against human PVRL4 were purchased from
Dharmacon using a predesigned ON-TARGET plus SMARTpool
siRNA (L-004301-00-0005). Non-targeting siRNA was used as a
negative control (D-001810-10-05). MCF7 and NCI-H358 cells
were plated at 30–40% confluence in 35-mm dishes a day before
siRNA transfection. One hundred picomoles of siRNA were mixed
with 5 ml of Lipofectamine 2000 (Invitrogen) in 500 ml Opti-MEM
(Invitrogen) and added to cells in 500 ml Opti-MEM. Cells were
transfected at 0 hrs and 10 hrs and incubated an additional 16 hrs.
At 26 hrs, Opti-MEM was replaced with DMEM containing 5%
FCS and cells were allowed to grow for an additional 48 h, and at
74 hrs into the experiment, cells were again transfected with siRNA
and incubated another 18 hrs. At 92 hrs into the experiment, cells
were inoculated with IC323-EGFP wtMV at an m.o.i of 5 for 2 hrs.
Following adsorption of virus, cells were treated with citrate buffer
to remove non-internalized virus, washed 3 times with PBS,
incubated with DMEM containing 5% FCS at 37uC for an
additional 36 hrs, and viewed by fluorescence and phase contrast
microscopy and then harvested to determine MV titres.
Virus titration
MV-infected cell monolayers were harvested in media and
subjected to one freeze-thaw cycle to release virus particles.
TCID50 titres were determined by 50% end-point titration on
Vero/hSLAM cells according to the Spearman-Ka ¨rber method.
Plaque assays using SeaPlaque agarose overlays were performed as
previously described [76].
MV binding assay
CHOpgsA745 cells that stably expressed PVRL4 were generated
from the pCMV6 AC-PVRL4 expression vector which contained a
neomycin
R selection marker. Cells were pre-treated with 15 mg/ml
of either blocking PVRL4 antibody (R&D Systems AF2659) or an
isotype control antibody (R&D Systems AB-108-C) for 30 minutes
at 4uC. To assess the binding capacity of MV to PVRL4, CHO-
PVRL4 cells were incubated with either 10 or 25 PFU/cell of MV-
IC323 for 90 minutes on ice in the presence of isotype (gIgG) or
blocking PVRL4 (gPVRL4) antibodies. Cells were washed three
times with PBS containing 1% bovine serum albumin, 5 mM
EDTA, and 0.1% sodium azide, and incubated with an anti-MV
hemagglutinin antibody (Millipore MAB8905) on ice for 60
minutes. The cells were washed prior to incubation with an alexa
fluor 488-conjugated goat anti-mouse antibody for 45 minutes on
ice. Cells were again washed to remove any unbound antibodies,
fixed in 1% paraformaldehyde, and run on a Cyan ADP Flow
Cytometer (Beckman Coulter). Data were processed using FCS
Express (De Novo Software). To determine the percentage of cells
that had MV bound to their surface, a marker was drawn on the
histogram so that the percentage of MV-bound cells in the mock
sample was 1%. All samples were compared to mock. Data were
graphed using GraphPad 4.0 software.
PVRL4 down regulation following IC323-EGFP wtMV
infection
B95a and MCF7 cells were seeded in 6-well plates at a density
of 1.5610
6 and 7.0610
5 cells per well, respectively. Cells were
allowed to grow for 24 h and then infected with IC323-EGFP
wtMV at 10 PFU/cell for 1.5 h. The virus innoculum was
replaced with DMEM containing 5% FCS and 100 mM of the
fusion inhibitory peptide, ZDfFG (Sigma C9405) to prevent
syncytia formation. Forty-eight hours post infection, cells were
harvested in non-enzymatic cell dissociation buffer (Sigma) and
stained for SLAM expression using SLAM antibody (BD
Biosciences) or PVRL4 expression as described above. Samples
were run on a Cyan ADP Flow Cytometer (Beckman Coulter) and
data processed using FCS Express (De Novo Software).
Accession number
Microarray data was deposited in the NCBI GEO database
(accession #GSE26636).
Figure 10. Mouse PVRL4 functions less efficiently as a MV receptor than the human homologue. COS-1 cells were transfected with
expression vectors encoding DDK-tagged human and mouse homologues of PVRL4. Control cells were transfected with empty plasmid. After 36 hrs,
the transfected cells were infected with IC323-EGFP wtMV and incubated a further 48 hrs. (A) Cells were viewed by fluorescence and phase contrast
microscopy. Scale bar =200 mm. (B) Virus released from the infected cells was quantified by plaque assay. Data are expressed as the mean from four
independent experiments, with error bars showing the SEM. (C) Total and cell surface expression was evaluated by Western immunoblots using
antibodies directed against the DDK(Flag) tag or PVRL4. Surface expression was evaluated following biotinylation of plasma membrane proteins. (D)
Viral proteins were synthesized in PVRL4 transfect cells following MV infection as shown by Western immunoblot using an antibody specific for the
viral matrix (M) protein.
doi:10.1371/journal.ppat.1002240.g010
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in susceptible breast adenocarcinoma, lung adenocarcinoma, and
serum activated SAEC.
(XLSX)
Acknowledgments
The authors thank D. Hoskin, P. Lee, C. McCormick, and R. Hill for some
of the cell lines used in these studies. IC323-EGFP wtMV and WTFH-
EGFP MV came from R. Cattaneo and is gratefully acknowledged. We
also thank E. Cowley for advice and use of the Millipore ERS-Epithelial
Voltohmmeter. We appreciate the Halifax Nordic Walkers for their
interest and encouragement for the work within our laboratory. We are
also grateful to J. Ho at the University Health Network/Princess Margaret
Hospital in Toronto for performing the immune histological analysis of
PVRL4 in human tissues.
Author Contributions
Conceived and designed the experiments: RSN DGB CDR. Performed the
experiments: RSN DGB GS CDR. Analyzed the data: RSN DGB LTL
CDR. Contributed reagents/materials/analysis tools: MNH LTL MST.
Wrote the paper: RSN CDR.
References
1. Enders JF, Katz SL, Holloway A (1962) Development of attenuated measles-
virus vaccines. A summary of recentinvestigation. Am J Dis Child 103: 335–340.
2. Moss WJ (2009) Measles control and the prospect of eradication. Curr Top
Microbiol Immunol 330: 173–189.
3. Blake FG, Trask JD (1921) Studies on Measles : I. Susceptibility of Monkeys to
the Virus of Measles. J Exp Med 33: 385–412.
4. de Swart RL (2009) Measles studies in the macaque model. Curr Top Microbiol
Immunol 330: 55–72.
5. Kobune F, Takahashi H, Terao K, Ohkawa T, Ami Y, et al. (1996) Nonhuman
primate models of measles. Lab Anim Sci 46: 315–320.
6. McChesney MB, Miller CJ, Rota PA, Zhu YD, Antipa L, et al. (1997)
Experimental measles. I. Pathogenesis in the normal and the immunized host.
Virology 233: 74–84.
7. Zhu YD, Heath J, Collins J, Greene T, Antipa L, et al. (1997) Experimental
measles. II. Infection and immunity in the rhesus macaque. Virology 233:
85–92.
8. Burnstein T, Jensen JH, Waksman BH (1964) The Development of a
Neurotropic Strain of Measles Virus in Hamsters and Mice. J Infect Dis 114:
265–272.
9. Griffin DE, Mullinix J, Narayan O, Johnson RT (1974) Age dependence of viral
expression: comparative pathogenesis of two rodent-adapted strains of measles
virus in mice. Infect Immun 9: 690–695.
10. Liebert UG, Finke D (1995) Measles virus infections in rodents. Curr Top
Microbiol Immunol 191: 149–166.
11. Blechacz B, Russell SJ (2008) Measles virus as an oncolytic vector platform. Curr
Gene Ther 8: 162–175.
12. Russell SJ, Peng KW (2009) Measles virus for cancer therapy. Curr Top
Microbiol Immunol 330: 213–241.
13. Griffin DE (2006) Measles Virus. In: Knipe D.M., editor in chief, Fields’
Virology. New York: Lippincott, Williams, and Wilkins. pp 1551–1585.
14. Navaratnarajah CK, Leonard VH, Cattaneo R (2009) Measles virus
glycoprotein complex assembly, receptor attachment, and cell entry. Curr
Top Microbiol Immunol 329: 59–76.
15. Hashiguchi T, Ose T, Kubota M, Maita N, Kamishikiryo J, et al. (2011)
Structure of the measles virus hemagglutinin bound to its cellular receptor
SLAM. Nat Struct Mol Biol 18: 135–141.
16. Navaratnarajah CK, Oezguen N, Rupp L, Kay L, Leonard VH, et al. (2011)
The heads of the measles virus attachment protein move to transmit the fusion-
triggering signal. Nat Struct Mol Biol 18: 128–134.
17. Yanagi Y, Takeda M, Ohno S, Hashiguchi T (2009) Measles virus receptors.
Curr Top Microbiol Immunol 329: 13–30.
18. Dorig RE, Marcil A, Chopra A, Richardson CD (1993) The human CD46
molecule is a receptor for measles virus (Edmonston strain). Cell 75: 295–305.
19. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, et al. (1993)
Human membrane cofactor protein (CD46) acts as a cellular receptor for
measles virus. J Virol 67: 6025–6032.
20. Kemper C, Atkinson JP (2009) Measles virus and CD46. Curr Top Microbiol
Immunol 329: 31–57.
21. Lecouturier V, Fayolle J, Caballero M, Carabana J, Celma ML, et al. (1996)
Identification of two amino acids in the hemagglutinin glycoprotein of measles
virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46
downregulation: phenotypic markers that differentiate vaccine and wild-type
MV strains. J Virol 70: 4200–4204.
22. Hsu EC, Sarangi F, Iorio C, Sidhu MS, Udem SA, et al. (1998) A single amino
acid change in the hemagglutinin protein of measles virus determines its ability
to bind CD46 and reveals another receptor on marmoset B cells. J Virol 72:
2905–2916.
23. Tahara M, Takeda M, Seki F, Hashiguchi T, Yanagi Y (2007) Multiple amino
acid substitutions in hemagglutinin are necessary for wild-type measles virus to
acquire the ability to use receptor CD46 efficiently. J Virol 81: 2564–2572.
24. Kobune F, Sakata H, Sugiura A (1990) Marmoset lymphoblastoid cells as a
sensitive host for isolation of measles virus. J Virol 64: 700–705.
25. Shibahara K, Hotta H, Katayama Y, Homma M (1994) Increased binding
activity of measles virus to monkey red blood cells after long-term passage in
Vero cell cultures. J Gen Virol 75(Pt 12): 3511–3516.
26. Bartz R, Firsching R, Rima B, ter Meulen V, Schneider-Schaulies J (1998)
Differential receptor usage by measles virus strains. J Gen Virol 79(Pt 5):
1015–1025.
27. Buckland R, Wild TF (1997) Is CD46 the cellular receptor for measles virus?
Virus Res 48: 1–9.
28. Tatsuo H, Ono N, Tanaka K, Yanagi Y (2000) SLAM (CDw150) is a cellular
receptor for measles virus. Nature 406: 893–897.
2 9 .H s uE C ,I o r i oC ,S a r a n g iF ,K h i n eA A ,R i c h a r d s o nC D( 2 0 0 1 )
CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus and
may account for the immunosuppressive properties of this virus. Virology 279:
9–21.
30. Erlenhoefer C, Wurzer WJ, Loffler S, Schneider-Schaulies S, ter Meulen V,
et al. (2001) CD150 (SLAM) is a receptor for measles virus but is not involved in
viral contact-mediated proliferation inhibition. J Virol 75: 4499–4505.
31. Schwartzberg PL, Mueller KL, Qi H, Cannons JL (2009) SLAM receptors and
SAP influence lymphocyte interactions, development and function. Nat Rev
Immunol 9: 39–46.
32. de Swart RL, Ludlow M, de Witte L, Yanagi Y, van Amerongen G, et al. (2007)
Predominant infection of CD150+ lymphocytes and dendritic cells during
measles virus infection of macaques. PLoS Pathog 3: e178.
Figure 11. Surface PVRL4 expression is down regulated following wtMV infection. (A) activated marmoset B-cell line B95a or (B) MCF7 cells
were infected with IC323-EGFP wtMV. The fusion inhibitory peptide (FIP) was added after the initial virus infection to prevent syncytia formation. At
48 h post-infection SLAM and PVRL4 surface expression was analyzed by FACS. Blue lines, mock-infected cells stained with alexa anti-SLAM antibody
(A) or anti-PVRL4 antibody (B); black lines, mock infected cells stained with the anti-mouse IgG2B isotype control antibody; filled orange histogram,
cells infected with IC323-EGFP wtMV (MOI=10) and stained with anti-SLAM (A) or anti-PVRL4 (B) antibodies, respectively. Alexa fluor conjugated 647
secondary antibodies were used to detect SLAM and PVRL4 surface expression. Insets, level of eGFP positive cells following a 48 h infection with
IC323-EGFP wtMV. The filled green histogram represents wtMV-infected cells; black lines represent mock-infected cells.
doi:10.1371/journal.ppat.1002240.g011
PVRL4 (Nectin 4) Is A Receptor for Measles Virus
PLoS Pathogens | www.plospathogens.org 23 August 2011 | Volume 7 | Issue 8 | e100224033. Leonard VH, Sinn PL, Hodge G, Miest T, Devaux P, et al. (2008) Measles virus
blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot
cross the airway epithelium and is not shed. J Clin Invest 118: 2448–2458.
34. Ludlow M, Rennick LJ, Sarlang S, Skibinski G, McQuaid S, et al. (2010) Wild-
type measles virus infection of primary epithelial cells occurs via the basolateral
surface without syncytium formation or release of infectious virus. J Gen Virol
91: 971–979.
35. Lemon K, de Vries RD, Mesman AW, McQuaid S, van Amerongen G, et al.
(2011) Early target cells of measles virus after aerosol infection of non-human
primates. PLoS Pathog 7: e1001263.
36. Craighead JE (2000) Pathology and pathogenesis of human viral disease. In:
Craighead JE, ed. Rubeola (Measles). Philadelphia: Elsevier Inc. pp 397–410.
37. Sakaguchi M, Yoshikawa Y, Yamanouchi K, Sata T, Nagashima K, et al. (1986)
Growth of measles virus in epithelial and lymphoid tissues of cynomolgus
monkeys. Microbiol Immunol 30: 1067–1073.
38. Griffin DE (2001) Measles Virus. In:Knipe D.M., editor in chief Fields’ Virology.
New York: Lippincott, Williams, and Wilkins. pp 1401–1442.
39. Takeuchi K, Miyajima N, Nagata N, Takeda M, Tashiro M (2003) Wild-type
measles virus induces large syncytium formation in primary human small airway
epithelial cells by a SLAM(CD150)-independent mechanism. Virus Res 94:
11–16.
40. Sinn PL, Williams G, Vongpunsawad S, Cattaneo R, McCray PB, Jr. (2002)
Measles virus preferentially transduces the basolateral surface of well-
differentiated human airway epithelia. J Virol 76: 2403–2409.
41. Tahara M, Takeda M, Shirogane Y, Hashiguchi T, Ohno S, et al. (2008)
Measles virus infects both polarized epithelial and immune cells by using
distinctive receptor-binding sites on its hemagglutinin. J Virol 82: 4630–4637.
42. Takeda M (2008) Measles virus breaks through epithelial cell barriers to achieve
transmission. J Clin Invest 118: 2386–2389.
43. Maisner A, Klenk H, Herrler G (1998) Polarized budding of measles virus is not
determined by viral surface glycoproteins. J Virol 72: 5276–5278.
44. Hashimoto K, Ono N, Tatsuo H, Minagawa H, Takeda M, et al. (2002) SLAM
(CD150)-independent measles virus entry as revealed by recombinant virus
expressing green fluorescent protein. J Virol 76: 6743–6749.
45. Shirogane Y, Takeda M, Tahara M, Ikegame S, Nakamura T, et al. (2010)
Epithelial-mesenchymal transition abolishes the susceptibility of polarized
epithelial cell lines to measles virus. J Biol Chem 285: 20882–20890.
46. Takeda M, Tahara M, Hashiguchi T, Sato TA, Jinnouchi F, et al. (2007) A
human lung carcinoma cell line supports efficient measles virus growth and
syncytium formation via a SLAM- and CD46-independent mechanism. J Virol
81: 12091–12096.
47. Barton ES, Forrest JC, Connolly JL, Chappell JD, Liu Y, et al. (2001) Junction
adhesion molecule is a receptor for reovirus. Cell 104: 441–451.
48. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG (1998)
Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1
and poliovirus receptor. Science 280: 1618–1620.
49. Coyne CB, Shen L, Turner JR, Bergelson JM (2007) Coxsackievirus entry across
epithelial tight junctions requires occludin and the small GTPases Rab34 and
Rab5. Cell Host Microbe 2: 181–192.
50. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, et al. (2009) Human
occludin is a hepatitis C virus entry factor required for infection of mouse cells.
Nature 457: 882–886.
51. Hsu EC, Sabatinos S, Hoedemaeker FJ, Rose DR, Richardson CD (1999) Use of
site-specific mutagenesis and monoclonal antibodies to map regions of CD46
that interact with measles virus H protein. Virology 258: 314–326.
52. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R (2004) Selectively receptor-
blind measles viruses: Identification of residues necessary for SLAM- or CD46-
induced fusion and their localization on a new hemagglutinin structural model.
J Virol 78: 302–313.
53. Hsu EC, Dorig RE, Sarangi F, Marcil A, Iorio C, et al. (1997) Artificial
mutations and natural variations in the CD46 molecules from human and
monkey cells define regions important for measles virus binding. J Virol 71:
6144–6154.
54. Riley RC, Tannenbaum PL, Abbott DH, Atkinson JP (2002) Cutting edge:
inhibiting measles virus infection but promoting reproduction: an explanation
for splicing and tissue-specific expression of CD46. J Immunol 169: 5405–5409.
55. Bonaparte MI, Dimitrov AS, Bossart KN, Crameri G, Mungall BA, et al. (2005)
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc
Natl Acad Sci U S A 102: 10652–10657.
56. Naniche D, Wild TF, Rabourdin-Combe C, Gerlier D (1993) Measles virus
haemagglutinin induces down-regulation of gp57/67, a molecule involved in
virus binding. J Gen Virol 74(Pt 6): 1073–1079.
57. Schneider-Schaulies J, Dunster LM, Kobune F, Rima B, ter Meulen V (1995)
Differential downregulation of CD46 by measles virus strains. J Virol 69:
7257–7259.
58. Bartz R, Brinckmann U, Dunster LM, Rima B, Ter Meulen V, et al. (1996)
Mapping amino acids of the measles virus hemagglutinin responsible for
receptor (CD46) downregulation. Virology 224: 334–337.
59. Tanaka K, Minagawa H, Xie MF, Yanagi Y (2002) The measles virus
hemagglutinin downregulates the cellular receptor SLAM (CD150). Arch Virol
147: 195–203.
60. Welstead GG, Hsu EC, Iorio C, Bolotin S, Richardson CD (2004) Mechanism of
CD150 (SLAM) down regulation from the host cell surface by measles virus
hemagglutinin protein. J Virol 78: 9666–9674.
61. Reymond N, Fabre S, Lecocq E, Adelaide J, Dubreuil P, et al. (2001) Nectin4/
PRR4, a new afadin-associated member of the nectin family that trans-interacts
with nectin1/PRR1 through V domain interaction. J Biol Chem 276:
43205–43215.
62. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, et al.
(2010) Nectin 4 overexpression in ovarian cancer tissues and serum: potential
role as a serum biomarker. Am J Clin Pathol 134: 835–845.
63. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, et al. (2009)
Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for
lung cancer. Cancer Res 69: 6694–6703.
64. Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, et al.
(2005) Nectin-4, a new serological breast cancer marker, is a substrate for tumor
necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 280:
19543–19550.
65. Meng W, Takeichi M (2009) Adherens junction: molecular architecture and
regulation. Cold Spring Harb Perspect Biol 1: a002899.
66. Mendelsohn CL, Wimmer E, Racaniello VR (1989) Cellular receptor for
poliovirus: molecular cloning, nucleotide sequence, and expression of a new
member of the immunoglobulin superfamily. Cell 56: 855–865.
67. Lopez M, Cocchi F, Menotti L, Avitabile E, Dubreuil P, et al. (2000)
Nectin2alpha (PRR2alpha or HveB) and nectin2delta are low-efficiency
mediators for entry of herpes simplex virus mutants carrying the Leu25Pro
substitution in glycoprotein D. J Virol 74: 1267–1274.
68. Taylor JM, Lin E, Susmarski N, Yoon M, Zago A, et al. (2007) Alternative entry
receptors for herpes simplex virus and their roles in disease. Cell Host Microbe
2: 19–28.
69. Yu Z, Adusumilli PS, Eisenberg DP, Darr E, Ghossein RA, et al. (2007) Nectin-1
expression by squamous cell carcinoma is a predictor of herpes oncolytic
sensitivity. Mol Ther 15: 103–113.
70. von Messling V, Milosevic D, Cattaneo R (2004) Tropism illuminated:
lymphocyte-based pathways blazed by lethal morbillivirus through the host
immune system. Proc Natl Acad Sci U S A 101: 14216–14221.
71. Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C,
et al. (2007) Nectin-4 is a new histological and serological tumor associated
marker for breast cancer. BMC Cancer 7: 73.
72. Bluming AZ, Ziegler JL (1971) Regression of Burkitt’s lymphoma in association
with measles infection. Lancet 2: 105–106.
73. Mota HC (1973) Infantile Hodgkin’s disease: remission after measles. Br Med J
2: 421.
74. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF (1981) Regression of
Hodgkin’s disease after measles. Lancet 1: 1112.
75. Zygiert Z (1971) Hodgkin’s disease: remissions after measles. Lancet 1: 593.
76. Richardson CD, Scheid A, Choppin PW (1980) Specific inhibition of
paramyxovirus and myxovirus replication by oligopeptides with amino acid
sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides.
Virology 105: 205–222.
PVRL4 (Nectin 4) Is A Receptor for Measles Virus
PLoS Pathogens | www.plospathogens.org 24 August 2011 | Volume 7 | Issue 8 | e1002240